US Stock Market Closed

Dashboard

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

B

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

CEO

John V. Oyler

Employees

3,500

Industry

-

Sector

-

Headquarters

-

Exchange

NASDAQ

Summary Stats

Market Cap

17.7B

Revenue

877M

Net Income

-1.91B

EPS

-$20.32

Price-to-Earnings

-8.43

Price-to-Book

3.01

Debt-to-Equity

0.36

News

Analyst Ratings

Price targets projected by 15 analysts

High

$359.00

Average

$297.20

Low

$135.00

Ratings calculated by 17 analysts

Buy

11

Hold

5

Sell

1

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Above by $0.49

Actual

-$4.24 +10.4%

Consensus

-4.73

Report Date

Year Ago

0.69

Year Ago Change %

Down 714%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites